Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 11/20 | 0.56 |
| ▸ | MTOR | P42345 | 10/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11027619 | 0.94 | PIK3CA (0.60) | PIK3CAMTORCCNE1CDK2KDR | |
| SCHEMBL2790005 | 0.90 | PIK3CA (0.62) | PIK3CAMTORCCNE1CDK2KDR | |
| SCHEMBL751149 | 0.89 | PIK3CA (0.57) | PIK3CAMTORCCNE1CDK2KDR | |
| SCHEMBL751735 | 0.87 | PIK3CA (0.54) | PIK3CAMTORCCNE1CDK2KDR | |
| SCHEMBL756108 | 0.87 | PIK3CA (0.59) | PIK3CAMTORCCNE1CDK2SMN1; SMN2 | |
| SCHEMBL752472 | 0.87 | PIK3CA (0.54) | PIK3CAMTORCCNE1CDK2KDR | |
| SCHEMBL2771022 | 0.86 | PIK3CA (0.62) | PIK3CAMTORCCNE1CDK2SMN1; SMN2 | |
| SCHEMBL11028397 | 0.86 | PIK3CA (0.59) | PIK3CAMTORCCNE1CDK2 | |
| SCHEMBL756457 | 0.85 | PIK3CA (0.56) | PIK3CAMTORSMN1; SMN2KDM4E | |
| SCHEMBL751742 | 0.85 | PIK3CA (0.52) | PIK3CAMTORCCNE1CDK2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | claimed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | claimed |
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | claimed |
| WO-2010132598-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC. (US) | 2010-11-18 | — | — | WO | claimed |
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | PIK3CA 1/4885MTOR 21/4885CCNE1 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.